It’s getting to the pointy end of Q4 CY2022, cardio protect data due soon.
US IND seems to be a “plan” so not necessarily a submission. But thinking ahead, what sort of cost would we be looking at and assuming this is simply a phase II and p3 not required under 505(b)2 pathway.
So back to my question, what is the cost of the trial trial and how will it be funded?
Ann: Quarterly Activity Report & Appendix 4C, page-22
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
